From: Expiratory central airway collapse in stable COPD and during exacerbations
No ECAC (n = 39) | ECAC (n = 25) | P value | |
---|---|---|---|
Age, years | 68 ± 12.5 | 73.4 ± 9.2 | 0.069 |
Gender (female:male) | 15:24 | 9:16 | 1.0 |
Body mass index (kg/m2) | 26.7 ± 7.4 | 25.6 ± 5 | 0.613 |
FEV1 (% predicted) | 48.4 ± 24.7 | 47.0 ± 21.2 | 0.843 |
FVC (% predicted) | 75.3 ± 20.4 | 70.8 ± 20.8 | 0.488 |
FEV1/FVC (% predicted) | 47.0 ± 18.2 | 48.7 ± 14.1 | 0.750 |
Bronchodilator response | 8.0 ± 8.5 | 4 ± 8 | 0.162 |
Pack years smoked | 60.6 ± 54.7 | 63.3 ± 58.8 | 0.880 |
TLCO (% predicted) | 42.2 ± 18.2 | 48.1 ± 19.7 | 0.357 |
Length of stay (days) | 4.4 ± 3.3 | 5.7 ± 6 | 0.267 |
Baseline mMRC dyspnea score | 2.2 ± 1.2 | 2.4 ± 1.2 | 0.404 |
Admission mMRC dyspnea score | 3.7 ± 0.5 | 3.7 ± 0.4 | 0.766 |
BAP65 (class - n) | I 6 II 17 III 12 IV 2 | I 1 II 8 III 9 IV 5 | 0.172 |
Oral prednisolone at admission (mg/day) | 3.9 ± 10.5 | 1.0 ± 2.2 | 0.201 |
Days on noninvasive ventilation | 0.3 ± 0.5 | 2.2 ± 2.6 | 0.197 |
Need for noninvasive ventilation (n) | 4 | 4 | 1.0 |
Death at 30 days (n) | 1 | 0 | 1.0 |
Hospital admissions in prior 12 months | 0.6 ± 1.3 | 1.0 ± 1.7 | 0.342 |
TBM | Sabre 3 Concentric 2 Crescentic 1 | Sabre 1 Concentric 3 Crescentic 0 | 0.732 |